TECHWIRE 30
(CIX: WRAL30)  1,092.79  down arrow-1.79  (-0.16 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NQ: Apple)  98.15  down arrow-0.23  (-0.23 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: QUINTILES)  56.82  up arrow+0.88  (1.57 %)  Updated: 06:40 PM EDT, Jul 30 2014
(OP: BASF SE)  107.09  down arrow-1.39  (-1.28 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: BioCryst)  12.86  up arrow+0.61  (4.98 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: BioDelivery)  13.42  up arrow+0.37  (2.84 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: CEMP)  9.64  down arrow-0.06  (-0.62 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: Cisco Systems)  25.63  down arrow-0.08  (-0.31 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: Cree)  48.71  up arrow+0.46  (0.95 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: DARA)  1.34  up arrow+0.01  (0.75 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: EMC CORPORATION)  29.90  up arrow+0.43  (1.46 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NQ: Extreme Networks)  4.80  up arrow+0.01  (0.21 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: FB)  74.68  up arrow+0.97  (1.31 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: GLAXOSMITHKLINE)  48.47  up arrow+0.44  (0.92 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NQ: GOOG)  587.42  up arrow+1.81  (0.31 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: IBM)  194.00  down arrow-0.57  (-0.29 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NY: LH)  105.87  up arrow+0.49  (0.47 %)  Updated: 06:40 PM EDT, Jul 30 2014
(OP: Lenovo Group)  27.06  down arrow-0.64  (-2.29 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: MRK)  58.08  down arrow-0.5  (-0.85 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NQ: Microsoft Corp)  43.58  down arrow-0.31  (-0.7 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: NTAP)  39.12  up arrow+0.54  (1.4 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: NOVARTIS AG)  88.44  up arrow+0.23  (0.26 %)  Updated: 06:40 PM EDT, Jul 30 2014
(OP: Novozymes A/S)  50.45  up arrow+0.01  (0.02 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: PFIZER)  29.26  down arrow-0.47  (-1.58 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NQ: Pozen)  7.36  up arrow+0.08  (1.1 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NY: RED HAT)  58.29  up arrow+2.14  (3.81 %)  Updated: 06:40 PM EDT, Jul 30 2014
(NQ: BBRY)  9.71  up arrow+0.2  (2.1 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: Salix)  135.26  up arrow+3.78  (2.88 %)  Updated: 05:20 PM EDT, Jul 30 2014
(NQ: SQI)  15.63  up arrow+0.52  (3.44 %)  Updated: 05:20 PM EDT, Jul 30 2014

Posts tagged “Novartis”

February 19, 2013

Premium Lock No $78M golden parachute deal for Novartis chairman

Daniel Vasella Daniel Vasella, who is stepping down as chairman of international drug firm Novartis, cancels his $78 million agreement to not work for rival drug makers.

January 24, 2013

Premium Lock Will Novartis vaccine plant in Holly Springs be on auction block?

As drug maker Novartis goes through a change at the top with Chairman Daniel Vasella stepping down, investors celebrate the move and call for the company to spin off some assets such as its vaccine business.

Novartis' plant in Holly Springs Novartis' plant in Holly Springs

January 23, 2013

Premium Lock Novartis chairman stepping down; top Bayer exec to replace him

Novartis Daniel Vasella, the controversial Swiss executive who created drugmaker Novartis, unexpectedly said he will leave the board after 17 years, handing over to Bayer AG's top health-care executive.

Updated November 21, 2012

Premium Lock FDA approves Novartis vaccine made at Holly Springs plant

The U.S. Food and Drug Administration gives approval for a seasonal influenza vaccine produced at Novartis' new, huge production facility in Holly Springs.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 25, 2012

Premium Lock Nebraska drug plant problems plaguing Novartis

Novartis Novartis, which operates a large production plant as well as a research and development operation in Holly Springs, N.C., says shutdown Nebraska plant is hurting its consumer sales.

August 29, 2012

Premium Lock Novartis smoker's cough drug beats GSK's Advair in trial

Lung disease Patients taking Novartis's QVA149 were able to expel more air from their lungs in one second than those receiving Glaxo's best-selling Advair after 26 weeks of treatment, according to a summary of data from a trial.

August 29, 2012

Premium Lock Novartis experimental heart-failure drug shows promise

Heart research If successful, LCZ696 would be the first drug for patients with preserved ejection fraction, a condition in which the organ's ventricles still pump out more than 40 percent of the blood that comes in, but the atrium chamber fails to supply enough blood to the ventricle to meet the body's needs. The condition, which mainly affects women, accounts for about half of all heart failure patients.

August 7, 2012

Premium Lock Novartis funds $20M cancer facility at U. of Pennsylvania

Cancer research In exchange for the funding, the drug giant gains rights to the university's cancer technology that utilizes manipulated immune system stem cells.

June 19, 2012

Premium Lock Novartis, GSK win big biodefense center contracts

Pandemic Novartis along with Duke and NCSU will create a center for biodefense and to combat pandemic influenza in Holly Springs under a $60 million contract with the U.S. Department of Health and Human Services. GSK will work with Texas A&M on a $176 million deal.

Updated December 12, 2011

Premium Lock NCSU scientists to help spread new Novartis vaccine technology

NC biotech group hails formal dedication of the massive $1 billion Novartis plant in Holly Springs.

Novartis plant in Holly Springs Novartis plant in Holly Springs

December 8, 2011

Premium Lock Novartis drug plant in Wilson on FDA warning list

Novartis The U.S. Food and Drug Administration is taking Novartis CEO Joseph Jimenez to task with a warning letter that cites three of the company's manufacturing facilities for "significant violations" at the company's generics drug unit Sandoz.

November 4, 2011

Premium Lock Life science awards go to PPD, Novartis, Steve Burrill

Life science Scrips, an international life science media and related services firm based in the U.K., honors PPD with two awards, Novartis with three, and names Burrill its lifetime achievement winner.

Updated October 25, 2011

Premium Lock Novartis to cut 2,000 jobs, close 3 European plants

The drug giant, which operates a huge vaccine production and research facility in Holly Springs, says some jobs will be moved to the US as well as China and India.

Novartis plant in Holly Springs Novartis plant in Holly Springs

October 20, 2011

Premium Lock Novartis: 'Contagion' is fiction but threat is real

The movie "Contagion" is fiction, but ask Novartis executive Russell Thirsk and he'll tell you the threats it depicts are quite real.

Click here to open the YouTube video in a new window.

September 6, 2011

Premium Lock Novartis fights patent rejection in Indian court

Novartis In a case that could affect India's role as drug provider to the developing world, the Supreme Court began hearing arguments Tuesday over whether the government had the right to deny a patent to Swiss drugmaker Novartis AG for its lifesaving cancer treatment Gleevec.

Tags: Novartis
April 19, 2011

Premium Lock Novartis earnings, sales top analysts' expectations

Novartis plant in Holly Springs Net income falls 6 percent but overall sales increase 16 percent from a year ago.

January 24, 2011

Premium Lock Novartis bids $470M for California-based cancer diagnostic firm

Novartis The Swiss drug maker, which is building a huge vaccine production plant in Holy Springs, is buying Genoptix.

December 22, 2010

Premium Lock Novartis to add 100 jobs, facilities at Holly Springs plant

The global life sciences firm will receive up to $3.7 million in state tax incentives for the expansion.

Novartis plant in Holly Springs Novartis plant in Holly Springs

November 16, 2010

Premium Lock Report: Novartis looking to buy as cash improves

Novartis The company is paying down debt from its Alcon purchase and looks to be debt-free in four years, the Financial Times said.

Tags: Novartis
Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Vivek Wadhwa
Commentary
Scroll